Core Viewpoint - The company announced the granting of stock options and restricted share units to incentivize employees and align their interests with the company's long-term growth and profitability [1] Group 1: Stock Options - On September 18, 2025, the company granted 6.7405 million stock options to 348 option grantees, pending acceptance by the grantees [1] - The purpose of granting stock options is to reward employees for their past contributions to the company's success and to encourage further contributions [1] Group 2: Restricted Share Units - On September 18, 2025, the company granted 1.9115 million restricted share units to 196 restricted share unit grantees, also pending acceptance [1] - The aim of granting restricted share units is to align the interests of eligible individuals with the group's interests through share ownership, thereby encouraging and retaining them for long-term growth and profitability [1]

智通财经APP讯，科济药业-B(02171)发布公告，于2025年9月18日，该公司根据首次公开发售后购股权 计划的条款向348名购股权承授人授出674.05万份购股权，惟须待购股权承授人接纳后方可作实。 公司授出购股权旨在奖励雇员过往对公司取得成功的贡献，以鼓励彼等进一步为公司作出贡献，并使其 利益与公司及股东的整体最佳利益保持一致。 董事会宣布，于2025年9月18日，公司根据首次公开发售后受限制股份单位计划的条款向196名受限制股 份单位承授人授出191.15万份受限制股份单位，惟须待受限制股份单位承授人接纳后方可作实。 授出受限制股份单位旨在通过拥有股份使合资格人士的利益与集团的利益一致，以鼓励及挽留彼等为集 团的长期增长及盈利作出贡献。 ...

Core Viewpoint - Company Kintor Pharmaceutical Co., Ltd. (02171.HK) announced the granting of stock options and restricted share units as part of its post-IPO incentive plans [1] Group 1: Stock Options - On September 18, 2025, the company granted a total of 6.7405 million stock options to 348 option grantees under the terms of its post-IPO stock option plan, pending acceptance by the grantees [1] Group 2: Restricted Share Units - On the same date, the company also granted 1.9115 million restricted share units to 196 grantees under the terms of its post-IPO restricted share unit plan, which is also subject to acceptance by the grantees [1]

CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2171） 香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (I) 根據首次公開發售後購股權計劃授出購股權；及 (II) 根據首次公開發售後受限制股份單位計劃授出受限制股份單位 (I) 根據首次公開發售後購股權計劃授出購股權 茲提述招股章程，內容有關於2021年11月30日採納的首次公開發售後購股權計劃 的主要條款。根據上市規則第17.06A條，董事會宣佈，於2025年9月18日，本公 司根據首次公開發售後購股權計劃的條款向348名購股權承授人授出6,740,500份 購股權，惟須待購股權承授人接納後方可作實。 授出購股權的詳情 向購股權承授人授出購股權之詳情如下： 授出購股權 每股股份20.99港元 的行使價： 購股權行使價每股股份20.99港元，相當於以下各項的較 高者：(i)聯交所 ...

Core Insights - Company Kogei Pharmaceuticals-B (02171.HK) announced the long-term follow-up results of its product Zevor-cel (CT053), a targeted BCMA autologous CAR-T cell therapy, which were presented at the 22nd International Myeloma Society (IMS) annual meeting [1] Group 1 - The updated results of the Phase I clinical trial for Zevor-cel were showcased in a poster presentation at the IMS annual meeting held on September 17, 2025, in Toronto [1]

Core Viewpoint - The long-term follow-up results of the CAR-T cell product Zevor-cel (CT053) for treating relapsed/refractory multiple myeloma were presented at the 22nd International Myeloma Society Annual Meeting [1] Group 1: Product Information - Zevor-cel is an autologous CAR-T cell product targeting BCMA, specifically designed for the treatment of multiple myeloma (MM) [1] - The product received approval from the National Medical Products Administration on February 23, 2024, for adult patients with relapsed or refractory multiple myeloma who have progressed after at least three lines of treatment [1] - Zevor-cel was granted Regenerative Medicine Advanced Therapy (RMAT) and orphan drug designation by the FDA in 2019 [1] Group 2: Clinical Trial Updates - The updated results of the Phase I clinical trial were presented under the title "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma" at the IMS annual meeting on September 17, 2025 [1]

Core Insights - The long-term follow-up results of the CAR-T cell product Zevor-cel (赛恺泽®) for treating relapsed/refractory multiple myeloma were presented at the 22nd International Myeloma Society (IMS) annual meeting [1] - Zevor-cel is an autologous CAR-T cell therapy targeting BCMA, approved by the National Medical Products Administration (NMPA) in China for adult patients with relapsed or refractory multiple myeloma who have undergone at least three lines of treatment [1] - The product received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug status in 2019, indicating its potential significance in treating rare diseases [1] Company Overview - 科济药业-B (02171) is focused on developing innovative therapies for hematological malignancies, with Zevor-cel being a key product in its pipeline [1] - The company aims to address unmet medical needs in the treatment of multiple myeloma, a challenging condition with limited effective therapies available [1] Clinical Development - The Phase I clinical trial results of Zevor-cel were updated and showcased at the IMS annual meeting, highlighting the ongoing commitment to research and development in the field of CAR-T therapies [1] - The long-term follow-up data is crucial for understanding the efficacy and safety profile of Zevor-cel in a real-world patient population [1]

Core Viewpoint - The long-term follow-up results of the CAR-T cell therapy product Zevor-cel for treating relapsed/refractory multiple myeloma have been presented at the 22nd International Myeloma Society (IMS) Annual Meeting [1] Group 1: Product Information - Zevor-cel (CT053) is a fully human anti-BCMA CAR-T cell product designed for the treatment of multiple myeloma (MM) [1] - The National Medical Products Administration approved Zevor-cel for marketing on February 23, 2024, for adult patients with relapsed or refractory multiple myeloma who have progressed after at least three lines of treatment [1] - The product has received the Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug status from the FDA in 2019 [1] Group 2: Clinical Trial Updates - The updated results of the Phase I clinical trial were presented on September 17, 2025, at the IMS Annual Meeting, focusing on long-term follow-up of patients treated with Zevor-cel [1] - The presentation was titled "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma" [1]

Core Insights - The company Kintor Pharmaceutical announced the long-term follow-up results of its CAR-T cell product, Zevor-cel, at the 22nd International Myeloma Society (IMS) annual meeting [1] Group 1 - The long-term follow-up results of the Phase I clinical trial for Zevor-cel were presented in a poster session at the IMS annual meeting [1] - The presentation was titled "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma" [1]

Core Viewpoint - The long-term follow-up results of the CAR-T cell product Zevor-cel (赛恺泽®) for treating relapsed/refractory multiple myeloma were presented at the 22nd International Myeloma Society Annual Meeting [1] Group 1: Product Information - Zevor-cel is an autologous CAR-T cell product targeting BCMA, specifically designed for the treatment of multiple myeloma (MM) [1] - The product received approval from the National Medical Products Administration on February 23, 2024, for use in adult patients with relapsed or refractory multiple myeloma who have progressed after at least three lines of treatment [1] - Zevor-cel was granted Regenerative Medicine Advanced Therapy (RMAT) and orphan drug designation by the FDA in 2019 [1] Group 2: Clinical Trial Updates - The updated results of the Phase I clinical trial were presented on September 17, 2025, at the IMS annual meeting, focusing on long-term follow-up for patients treated with Zevor-cel [1] - The presentation was titled "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma" [1]